IMMUNOCORE HLDGS ADS/1 (6YG) - Total Assets
Based on the latest financial reports, IMMUNOCORE HLDGS ADS/1 (6YG) holds total assets worth €1.07 Billion EUR (≈ $1.25 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 6YG cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
IMMUNOCORE HLDGS ADS/1 - Total Assets Trend (2022–2025)
This chart illustrates how IMMUNOCORE HLDGS ADS/1's total assets have evolved over time, based on quarterly financial data. See IMMUNOCORE HLDGS ADS/1 net assets for net asset value and shareholders' equity analysis.
IMMUNOCORE HLDGS ADS/1 - Asset Composition Analysis
Current Asset Composition (December 2025)
IMMUNOCORE HLDGS ADS/1's total assets of €1.07 Billion consist of 93.4% current assets and 6.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 43.8% |
| Accounts Receivable | €73.98 Million | 6.9% |
| Inventory | €6.74 Million | 0.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how IMMUNOCORE HLDGS ADS/1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IMMUNOCORE HLDGS ADS/1 stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IMMUNOCORE HLDGS ADS/1's current assets represent 93.4% of total assets in 2025, an increase from 90.0% in 2022.
- Cash Position: Cash and equivalents constituted 43.8% of total assets in 2025, down from 76.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 6.9% of total assets.
IMMUNOCORE HLDGS ADS/1 Competitors by Total Assets
Key competitors of IMMUNOCORE HLDGS ADS/1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
IMMUNOCORE HLDGS ADS/1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.04 | 4.38 | 4.38 |
| Quick Ratio | 4.01 | 4.36 | 4.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €750.04 Million | €717.68 Million | €717.68 Million |
IMMUNOCORE HLDGS ADS/1 - Advanced Valuation Insights
This section examines the relationship between IMMUNOCORE HLDGS ADS/1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.79 |
| Latest Market Cap to Assets Ratio | 1.27 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | €1.07 Billion |
| Market Capitalization | $1.36 Billion USD |
Valuation Analysis
Above Book Valuation: The market values IMMUNOCORE HLDGS ADS/1's assets above their book value (1.27x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: IMMUNOCORE HLDGS ADS/1's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below shows the annual total assets of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.07 Billion ≈ $1.25 Billion |
+5.72% |
| 2024-12-31 | €1.01 Billion ≈ $1.18 Billion |
+69.10% |
| 2023-12-31 | €597.00 Million ≈ $697.96 Million |
+13.33% |
| 2022-12-31 | €526.76 Million ≈ $615.84 Million |
-- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more